The latest biotech news

News and Trends 3 May 2015

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III. This innovative compound is […]

May 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

Newron raised new funds to continue the development of Neurological therapies

Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be used to accelerate the development of Newron’s pipeline of innovative CNS therapeutics: The company priority seems to be on NW-3509, an add-on therapy for schizophrenia, for […]

May 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

PlugMed has been awarded €2 million of funding, as part of the World Innovation Challenge organized by the French Ministry of Industry. It will enable the company to speed up the Geroneph project that aims at developing an innovative device in the treatment of kidney failure. Nowadays, dialysis is used by more than two million people […]

May 2, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 1 May 2015

Galderma steps into the Nutraceutical Market

Galderma entered the functional food market thanks to its acquisition of certain assets of Innéov Group. The company, a global leader committed to dermatology and skin health, is fully-owned by Nestlé Skin Health. On April 24th Nestlé Skin Health announced that Galderma, its company focused on medical solutions, has come to an agreement under which it […]

May 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 1 May 2015

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Biotech startups are risky. They need lot of cash to come across the very regulated clinical path and can fail rapidly when bad results show up. Addex Therapeutics, a Swiss Geneva-based Biotech company, has raised more than €200M throughout its existence and signed deals worth more than €1Bn with Merck and J&J. Yet, on the 31st May 2013, the company almost […]

May 1, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Biocartis shakes Euronext with an IPO that raised €100M

Last Monday, Belgian Biocartis launched an IPO that quickly raised €100M; the offering was closed a week ahead of schedule. The unquestionable interest of the investors, both in Belgium and internationally, shows the company’s potential and the appeal of its technology. The company, which raised €64.5M in September in a private financial round, intends to […]

April 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 29 Apr 2015

Cytena greets €1.1M of Seed Capital

Cytena and its cy-Clone device to separate single cells received €1.1M from a consortium made up of a private investor and the High-Tech Gründerfonds (HTGF). Cytena will use this capital injection primarily to launch its product and to expand its marketing and distribution activities. The cy-Clone, cytena’s newest innovation, is a laboratory device that enables the […]

April 29, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

European GMOs: which side are you on?

Last week, the European Commission approved 19 GMOs, the first authorizations since 2013. Shortly after, different reactions showed up, with some people more willing to celebrate than others. While GMOs are widely grown in America and Asia, Europe is still reluctant to this new technology. These authorizations came after a year of European blockage. But […]

April 29, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 Apr 2015

Giant Baupost Group bets on Biotie

Finland-based Biotie Therapies will receive an investment of more than €92M from Baupost group. However, the investment is conditional and linked to the result of the appointment of a new board member expected for the 26th of May. Seth Klarman’s billionaire Baupost group will back Biotie on its way to develop tozadenant, its lead product candidate. The […]

April 29, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 28 Apr 2015

PEP-Therapy Raised €1.3 Million in Seed Capital

France-based PEP-Therapy has raised €1.3M in initial funding. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable the cancer-focused company to undertake regulatory development of its first therapeutic product, a biomarker. The biomarker works as a predictive for foreseeing the effectiveness of a cancer treatment. The […]

April 28, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Newron raised new funds to continue the development of Neurological therapies

PlugMed has Just Won €2M Funding to Develop an Innovative Device against Kidney Failure

Galderma steps into the Nutraceutical Market

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

A new Microfluidic Chip technology raised €1.9Million

Biocartis shakes Euronext with an IPO that raised €100M

Cytena greets €1.1M of Seed Capital

European GMOs: which side are you on?

Giant Baupost Group bets on Biotie

PEP-Therapy Raised €1.3 Million in Seed Capital

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!